NCT02192021View on ClinicalTrials.gov

Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL)

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 9, 2016

Primary Completion Date

November 21, 2020

Study Completion Date

December 9, 2020

Conditions
Cutaneous T Cell Lymphoma
Interventions
DRUG

Micro needle array-Doxorubicin (MNA-D)

MNA-D patches will be applied to 3-4 CTCL skin patches or plaques at each weekly visit (4/cycle). The initial safety, dose-finding phase will include one cycle of applications and the second phase will include weekly applications (4/cycle) for up to 6-8 cycles.

Trial Locations (1)

15213

UPMC Department of Dermatology, Pittsburgh

All Listed Sponsors
lead

Falo, Louis, MD

OTHER

NCT02192021 - Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL) | Biotech Hunter | Biotech Hunter